Our Response to COVID-19
Despite the constantly challenging environment the COVID-19 pandemic has presented to the world, we have remained steadfast in our promise to safeguard public health. As the pandemic continues to evolve, so have we. We have redirected resources and taken on extra commitments to protect public health where we could offer the most value, including our expertise, technologies, equipment and materials.
We're committed to the fight against influenza
At Seqirus, we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year.
Seqirus is one of the world’s largest influenza vaccine companies. We were created when our parent company, CSL Limited, acquired the Novartis influenza vaccine business and combined it with vaccine subsidiary, bioCSL.
This website is intended for people seeking information on Seqirus' worldwide business.
Our country sites can be located in our Worldwide Directory.
GBR-FLU-0006 February 2021